No longer operating. CELLforCURE (SEQENS) has closed or wound down its CDMO business. It is left out of search results and rankings, and this profile is kept as a record.

CELLforCURE (SEQENS)

Les Ulis, FR
Find alternatives to CELLforCURE (SEQENS) for CAR-T →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
80.3
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ✓ EMA GMP (4) ○ MHRA GMP

Quick Facts: CELLforCURE (SEQENS)

Signal Score
80.3/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Clean EMA record: 4 active GMP certificates (no deductions)
Headquarters
Les Ulis, FR
Modalities
CAR-T, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About CELLforCURE (SEQENS)

French cell therapy CDMO, part of SEQENS group.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Clean EMA record: 4 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 4 active GMP certificates (no deductions)
FDA InspectionsNo US records on file
EMA GMP Certificates4 on record
Clean EMA record: 4 active GMP certificates (no deductions)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: SEQENS
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: SEQENS
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Les Ulis, France
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Les Ulis, France
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Les Ulis, France
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

CELLforCURE (SEQENS) EMA GMP Compliance 4 certificates

2022-06
2022-06
2022-06
2022-06
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
2022_HPF_FR_173_IV_P_2025 Cellforcure France 2022-06-10 COMPLIANT
2022_HPF_FR_174_IV_P_2025 Cellforcure France 2022-06-10 COMPLIANT
2022_HPF_FR_173_IV Cellforcure France 2022-06-10 COMPLIANT
2022_HPF_FR_174_IV Cellforcure France 2022-06-10 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Frequently Asked Questions About CELLforCURE (SEQENS)

Does CELLforCURE (SEQENS) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA GMP certificates for CELLforCURE (SEQENS).
What is CELLforCURE (SEQENS)'s CDMO Signal Score?
CELLforCURE (SEQENS) has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating CELLforCURE (SEQENS) for a manufacturing program?
Use the free AI matchmaker to compare CELLforCURE (SEQENS) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody

Compare CELLforCURE (SEQENS) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on CELLforCURE (SEQENS)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.